Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment

Documenti analoghi

• Early detection of left ventricular dysfunction in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor (Imatinib): using global longitudinal strain
  di: Bassim Shnain Jassim
  Pubblicazione: (2020)
• JAK2-mutated acute myeloid leukemia: comparison of next-generation sequencing (NGS) and single nucleotide polymorphism array (SNPa) findings between two cases
  di: Thiago Rodrigo de Noronha
  Pubblicazione: (2019)
• Supplementary Data: Identification of hematopoietic cell state markers in acute leukemia using explainable machine learning
  di: Chen, David
  Pubblicazione: (2025)
• Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL
  di: Tomas-Navarro, Jose, et al.
  Pubblicazione: (1998)
• Factor VIII delivery devices in haemophilia A. Barriers and drivers for treatment adherence
  di: Isabel Fernández-Arias
  Pubblicazione: (2016)